{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:59:23Z","timestamp":1785308363487,"version":"3.55.0"},"reference-count":28,"publisher":"Wiley","issue":"15","license":[{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Thoracic Cancer"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The efficacy and safety of osimertinib combined with bevacizumab in non\u2010small cell lung cancer (NSCLC) patients with brain metastasis harboring epidermal growth factor receptor (<jats:italic>EGFR<\/jats:italic>) mutations have not been fully studied.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Treatment\u2010na\u00efve NSCLC patients with brain metastasis harboring <jats:italic>EGFR<\/jats:italic>\u2010activating mutations were treated with osimertinib 80\u2009mg oral daily and bevacizumab 15\u2009mg\/kg intravenously on day 1, repeated every 21\u2009days, until disease progression, intolerable toxicity, or death. The primary endpoint was the median progression\u2010free survival (mPFS), and the secondary endpoints were the median overall survival (mOS), response rates, and toxicities. This study has been registered in <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link> (NCT05104281) and is ongoing.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 52 Chinese patients were enrolled, of whom 17 harbored <jats:italic>EGFR<\/jats:italic> 19 del and 35 harbored <jats:italic>EGFR<\/jats:italic> L858R mutation. The objective response rate (ORR) was 75.0% and the disease control rate (DCR) was 96.2%; the mPFS was 17.0\u2009months (95% CI: 11.46\u201322.54), while the mOS was not reached. The mPFS was 20.0\u2009months (95% CI: 14.56\u201325.44) and was 17.0\u2009months (95% CI: 13.28\u201320.72) for patients harboring <jats:italic>EGFR<\/jats:italic> 19 del and <jats:italic>EGFR<\/jats:italic> L858R mutation (<jats:italic>p<\/jats:italic>\u2009=\u20090.844), respectively. The intracranial ORR was 82.7%, and the intracranial mPFS was 22.0\u2009months (95% CI: 2.92\u201341.08).The main adverse events were mild\u2010to\u2010moderate hand\u2010foot syndrome, diarrhea, hypertension, and proteinuria. Three patients developed grade III proteinuria, while five patients developed grade III hypertension; they permanently discontinued bevacizumab treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Osimertinib combined with bevacizumab shows promising results in <jats:italic>EGFR<\/jats:italic>\u2010mutated NSCLC patients with brain metastasis, and the side effects are tolerable.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1759-7714.14880","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T07:36:22Z","timestamp":1680680182000},"page":"1355-1361","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Osimertinib combined with bevacizumab as the first\u2010line treatment in non\u2010small cell lung cancer patients with brain metastasis harboring epidermal growth factor receptor mutations"],"prefix":"10.1111","volume":"14","author":[{"given":"Ling","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Oncology Affiliated Qingdao Central Hospital of Qingdao University, Qingdao Cancer Hospital  Qingdao 266042 China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhong","family":"You","sequence":"additional","affiliation":[{"name":"Department of Oncology Affiliated Qingdao Central Hospital of Qingdao University, Qingdao Cancer Hospital  Qingdao 266042 China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueli","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology Affiliated Qingdao Central Hospital of Qingdao University, Qingdao Cancer Hospital  Qingdao 266042 China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengjuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology Affiliated Qingdao Central Hospital of Qingdao University, Qingdao Cancer Hospital  Qingdao 266042 China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2895-4730","authenticated-orcid":false,"given":"Keke","family":"Nie","sequence":"additional","affiliation":[{"name":"Department of Oncology Affiliated Qingdao Central Hospital of Qingdao University, Qingdao Cancer Hospital  Qingdao 266042 China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2303-8784","authenticated-orcid":false,"given":"Youxin","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Oncology Affiliated Qingdao Central Hospital of Qingdao University, Qingdao Cancer Hospital  Qingdao 266042 China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,4,5]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21654"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000022815"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.3741"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2016-0163-SA"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000422"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810699"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30033-X"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1913662"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70184-X"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.11498"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.11.020"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.1260"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00166-1"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.11.010"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2015.01.020"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02840-0"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.3171\/2017.2.JNS161659"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.07.005"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-040023"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1586\/era.11.80"},{"key":"e_1_2_10_23_1","unstructured":"BesseB Le MoulecS Mazi\u00e8resJ SenellartH.Bevacizumab in Patients with Non\u2010Squamous Non\u2010Small\u2010Cell Lung Cancer and Asymptomatic Untreated Brain Metastases (BRAIN): a Non\u2010Randomised Phase II Study. n.d."},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-08449-w"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.18632\/aging.103455"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(17)30262-X"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2018.125"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.06.017"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-020-03615-4"}],"container-title":["Thoracic Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1759-7714.14880","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T16:45:18Z","timestamp":1692549918000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1759-7714.14880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,5]]},"references-count":28,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1111\/1759-7714.14880"],"URL":"https:\/\/doi.org\/10.1111\/1759-7714.14880","archive":["Portico"],"relation":{},"ISSN":["1759-7706","1759-7714"],"issn-type":[{"value":"1759-7706","type":"print"},{"value":"1759-7714","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,5]]},"assertion":[{"value":"2023-02-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}